Yksityisyysasetukset
Inderes käyttää evästeitä tarjotakseen paremman käyttökokemuksen ja henkilökohtaisemman palvelun. Hyväksymällä evästeiden käytön voimme kehittää palvelua entistä paremmin ja pystymme tarjoamaan sinua kiinnostavaa sisältöä.
  • Foorumi
  • Premium
  • Osakemarkkinat
    • PörssiReaaliaikaiset kurssit, indeksit ja markkinakehitys
    • AamukatsausPäivittäinen markkinakatsaus ja yön tärkeimmät tapahtumat
    • PörssikalenteriTulevat tulokset, listautumiset ja yritystapahtumat
    • OsinkokalenteriTulevat ja menneet osingot
  • Yhtiöt
    • YhtiötSelaa ja suodata listattujen yhtiöiden listaa
    • Löydä osakkeitaInspiraatiota seuraavaan sijoitukseesi
    • ListautumisetUudet listautumiset ja tulevat pörssiannit
    • YhtiökokouskutsutYhtiökokousten päivämäärät ja osakkeenomistajatiedot
  • Osaketutkimus
    • AnalyysiAsiantuntijoiden osakeanalyysi ja suositukset
    • ArtikkelitUutiset, näkemykset ja markkinakommentit
    • MallisalkkuInderesin mallisalkku
    • FemmeRohkeutta ja itseluottamusta sijoittamiseen
  • Opi sijoittamisesta
    • AnalyysikouluOpi lukemaan ja ymmärtämään osakeanalyysiä
    • SijoituskouluOppaita ja oppitunteja sijoitusosaamisen kasvattamiseen
    • SalkunhaltijatSijoitustietoa jokaiselle tasolle, ensiaskeleista edistyneisiin salkkustrategioihin.
    • inderesTVVideokeskus osaketutkimukselle, analyysille ja asiantuntijakommenteille
    • TranskriptitTulosjulkistusten ja sijoittajatapaamisten tekstimuotoiset tallenteet
    • OsakevertailuVertaa tunnuslukuja ja kehitystä useiden osakkeiden välillä
    • TuloskausiVertaile EPS-ennusteita toteutuneisiin tuloksiin
    • Sisäpiirin kaupatSeuraa yhtiöiden sisäpiiriläisten osto- ja myyntitoimintaa
    • LyhyeksimyyntiKatso, millä pörssiyhtiöillä on ilmoitettuja lyhyitä positioita
    • Virtuaalinen analyytikkochatEsitä kysymyksiä ja saa tekoälypohjaisia sijoitusnäkemyksiä
    • Korkoa korolle -laskuriLaske, miten säästösi kasvavat korkoa korolle -ilmiön ansiosta.
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Q&A
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Kaikki markkinat
Suomi
Ruotsi
Tanska
Norja
Uusimmat
Suositut
Seuratut

Scandion Oncology, Audiocast with teleconference, Q3'24

Julkaissut Inderes11.11.2024 klo 8.00
Scandion Oncology

Huomio: Tämä on koneellisesti luotu transkripti ja se saattaa sisältää epätarkkuuksia.

Francois Martelet
00:00 - 05:24

Good morning, everyone, and thank you for attending this quarterly call for 2024. Uh, could I have the next slide, please? Which is the disclaimer. The classical disclaimer is that we will not go through the next slide. So together with me, we have Johnny Stilou, our CFO, and I will quickly go through the clinical updates. Then Johnny will go through the financial performance, and then I will update you about our partnering activities. Next slide, please. Yes. All right. So you can see us. Next slide. Right. So, as most of you likely know, we are involved in Colorectal Cancer. We are a drug resistance company. One of the first companies actually in this setting. And we have, over the last few years, engaged in a program called CORIST. And, with our compound, our lead compound, SCO-101, which is a small molecule combined with FOLFIRI, we've advanced from phase one to phase two, and now we are in phase two A. We are certainly expecting the final data to be released early. In 2025, we released the top-line data, which are positive phase 2A data. And we will be releasing the final data analysis early in 2025. So, for colorectal cancer, this pertains to the CORIST program. And I will go into more details later on. PANTAX is our clinical trial in pancreatic cancer. This is a phase 1B. We have released the data earlier this year that show good tolerability, good safety with a combination of nab-paclitaxel and gemcitabine and, of course, SCO-101. At the same time, you know, we engaged earlier in gastric cancer and have been able to release some good preclinical data for this indication. Therefore, we are ready to engage in a phase 1B2A. At the same time, mainly due to cost constraints, we have not been able to continue the preclinical development program with SCO-201. But this is certainly an asset that could also potentially be used in other indications beyond oncology, like HIV, and that asset is currently on hold from a preclinical development perspective. Should I have the next slide, please? Right. So here are a bit more details about CORIST. So we've been able to release the top-line data earlier in the year. We've been able to demonstrate a good safety and tolerability profile. Something which is very important in oncology is, of course, partial responses. And in the last cohort where we've been able to demonstrate our MTD, we have got two PRs. And this is extremely encouraging for us and for the patients. Of course, at the same time, we've been able to show a significant overall survival, which is in the range of 8 to 10 months. And also, if we are selecting a subgroup of patients expressing one type of UGT1A1, then we've been able to increase the overall survival up to 13 months, which is significant. I know, of course, that this is based on a limited set of patients, but at least we have to start somewhere. And obviously, this can only be encouraging for the future development of our clinical trial. So the conclusion is that we've been able to achieve an MTD (maximum tolerated dose) for the four-day schedule using SCO-101 in combination with FOLFIRI, meaning that we have 50% oenothera dosage and 100% Leucovorin and 5-FU. And then the result is that we have an MTD at 250 mg per day of SCO-101. So altogether, this is extremely encouraging for continuing the development of our clinical development plan for colorectal cancer with SCO-101. Next slide, please. So this is for Johnny. Johnny, please go ahead.

Johnny Stilou
05:24 - 07:19

Thank you. Yes, this is the financial overview. And as you can see, the third quarter of 2024 ended with a net loss of 6.7 million Danish kroner. This is compared to the same quarter last year, where we had a net loss of 10.1 million Danish kroner. The reduction in loss and cost is driven by reduced clinical costs, as our two clinical programs have been downscaled. Our cash position at the end of September, the end of the quarter, ended with a balance of 14.8 million Danish kroner. Now, with this number. Bear in mind that we have a tax credit due of 5.5 million Danish kroner, which we receive annually due to our clinical costs, clinical programs. And this money, 5.5 million Danish kroner, we will receive for this year later in this month, in November. But as of the end of September, we had 14.8 million Danish kroner. With that cash position, we are able to fund the operation into the fourth quarter of next year, 2025. And here on the next slide, you can see graphically that our cost is being reduced quarter over quarter. And we expect the same reduction in quarter-over-quarter costs to continue into 2025, which is why, as just mentioned, our current cash position will sustain us into the fourth quarter of 2025. With that, I will hand the word back to Francois.

Francois Martelet
07:20 - 10:19

Thank you, Johnny. So, if I could summarize where we stand now. As you know, we are a drug resistance company. We are one of the first movers in this direction. And with our SCO-101, potentially we have a first-in-class drug inhibitor. And we are targeting two targets, CPG2 and UGT1A1, as you know. So we are really a precision anti-cancer drug company. We've been able to demonstrate good data from a phase 2A in colorectal cancer. Also, some good data in phase 1B in pancreatic cancer. And certainly, our compound has broad commercial potential not only in those indications but also in others that could be further developed depending on our financial position. Financially speaking, we've been able to control costs very drastically. And as Johnny said, we are able to finance the company into Q4 2025. Obviously, what's next? As most of you have understood, we are now in the middle of the development process for colorectal cancer. Having achieved good phase two. Having achieved good phase two A, so now we need to move the pipeline towards phase 2B/3. In order to do that, we certainly need additional funding, and performing a phase 2B3 in colorectal cancer requires hundreds of patients. Therefore, from a financial perspective, we need to have a partner, given the market conditions, given where we stand as a publicly listed company. A partner is absolutely needed in order to continue this development program. And this is exactly what I am focusing all my efforts on, together with Johnny and our CMO and our CSO. And on that side, I'm sure you will appreciate some confidential information that I cannot disclose, but be absolutely sure that we are doing our utmost to find a partner. And of course, we will be releasing good news whenever available. And I will not say more about that. But again, rest assured that our commitment is 100% towards these development activities. Uh, next slide please. And this will conclude our brief presentation today, and I am open to any questions you may have. Slide set today, and I am open to any questions you may have. Back to you. Operator, please.

Operator
10:21 - 10:54

Thank you. If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. We'll have a brief pause while questions are being registered. There seem to be no questions. So, I hand the word back to you, Francois and Johnny.

Francois Martelet
10:57 - 11:13

Thank you. Thank you to the audience for listening to us today on this important but short call. And again, we will be updating the market as soon as we have news on the business development side. Thank you very much. And have a good day.

Katso webcast
Revenio Group Oyj, Q3'26
Kieli: englanti12.11.2026 klo 13.00
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Kieli: englanti12.11.2026 klo 9.00
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Kieli: suomi12.11.2026 klo 8.00
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Kieli: suomi11.11.2026 klo 9.00
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Kieli: englanti10.11.2026 klo 11.00
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Kieli: suomi10.11.2026 klo 10.00
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Kieli: englanti10.11.2026 klo 9.00
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Kieli: englanti9.11.2026 klo 12.00
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Kieli: englanti6.11.2026 klo 12.30
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 13.00
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Kieli: englanti5.11.2026 klo 11.00
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 10.30
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Kieli: englanti5.11.2026 klo 10.00
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 9.00
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Kieli: englanti5.11.2026 klo 8.30
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 8.00
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 7.30
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 12.00
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Kieli: suomi4.11.2026 klo 9.00
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 8.30
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…